RNS Number : 9286E
PureTech Health PLC
22 July 2016
 

For filings with the FCA include the annex

 

For filings with issuer exclude the annex

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

   
  
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:ii
PureTech Health Plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
X
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
  
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
  
An event changing the breakdown of voting rights
 
Other (please specify):
  
  
3. Full name of person(s) subject to the
notification obligation:iii
Baillie Gifford & Co
4. Full name of shareholder(s)
(if different from 3.):iv
  
5. Date of the transaction and date on
which the threshold is crossed or
reached:v
20 July 2016
6. Date on which issuer notified:
21 July 2016
7. Threshold(s) that is/are crossed or
reached: vi, vii
5%

 

 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary

Share

GB00BY2Z0H74

 

 

Below 5%

 

 

Below 5%

 

 

12,529,837

 

5.28%

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date xiii

Exercise/
Conversion Period xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

N/A

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date xvii

Exercise/
Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

N/A

 

 

 

 

 

Nominal

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

12,529,837

5.28%

                 
 

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi

 

In the narrative below, the figures in [ ] indicate the amount of voting rights and the percentage held by each controlled undertaking where relevant.

Baillie Gifford & Co, a discretionary investment manager, is the parent undertaking of an investment management group.

 Its wholly-owned subsidiary undertaking Baillie Gifford Overseas Limited [3,421,563:1.44%] is also a discretionary investment manager.

Its wholly-owned subsidiary undertaking Baillie Gifford & Co Limited [4,011,350:1.69%] is an OEIC Authorised Corporate Director and Unit Trust Manager which has delegated its discretionary investment management role to Baillie Gifford & Co.

Its wholly-owned subsidiary undertaking Baillie Gifford Life Limited [1,697,490:0.72%] is a life assurance company which procures discretionary investment management services from Baillie Gifford & Co in respect of its own account shareholdings.

 

 

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

 

12. Date on which proxy holder will cease to hold voting rights:

 

 


13. Additional information:


 

14. Contact name:

Mike Bassi

15. Contact telephone number:

0131 275 3852

   

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLRBMBTMBJTTAF